BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $25.11 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. decreased its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 10.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 491,381 shares of the company’s stock after selling 54,853 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Crinetics Pharmaceuticals were worth $25,110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of CRNX. AQR Capital Management LLC increased its position in shares of Crinetics Pharmaceuticals by 3.3% during the second quarter. AQR Capital Management LLC now owns 7,126 shares of the company’s stock valued at $319,000 after purchasing an additional 227 shares during the period. US Bancorp DE boosted its stake in Crinetics Pharmaceuticals by 3.4% during the third quarter. US Bancorp DE now owns 11,488 shares of the company’s stock worth $587,000 after buying an additional 373 shares in the last quarter. KBC Group NV increased its holdings in Crinetics Pharmaceuticals by 22.8% in the 3rd quarter. KBC Group NV now owns 2,193 shares of the company’s stock valued at $112,000 after buying an additional 407 shares during the period. Amalgamated Bank raised its stake in shares of Crinetics Pharmaceuticals by 20.8% in the 2nd quarter. Amalgamated Bank now owns 2,692 shares of the company’s stock valued at $121,000 after buying an additional 464 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Crinetics Pharmaceuticals by 2.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 20,633 shares of the company’s stock worth $1,054,000 after acquiring an additional 505 shares during the period. Institutional investors own 98.51% of the company’s stock.

Insider Buying and Selling at Crinetics Pharmaceuticals

In other Crinetics Pharmaceuticals news, CFO Marc Wilson sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $51.11, for a total transaction of $1,277,750.00. Following the transaction, the chief financial officer now directly owns 111,092 shares in the company, valued at approximately $5,677,912.12. This represents a 18.37 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $54.63, for a total transaction of $785,306.25. Following the sale, the insider now owns 28,507 shares of the company’s stock, valued at approximately $1,557,337.41. This represents a 33.52 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,410 shares of company stock worth $2,275,929. Insiders own 6.00% of the company’s stock.

Crinetics Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:CRNX opened at $56.06 on Friday. The firm has a market cap of $5.20 billion, a P/E ratio of -15.03 and a beta of 0.62. Crinetics Pharmaceuticals, Inc. has a 12 month low of $30.50 and a 12 month high of $62.53. The company’s 50-day moving average price is $55.32 and its two-hundred day moving average price is $51.50.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same quarter last year, the company earned ($1.01) EPS. As a group, equities analysts predict that Crinetics Pharmaceuticals, Inc. will post -3.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRNX has been the topic of a number of analyst reports. JMP Securities reissued a “market outperform” rating and issued a $80.00 target price on shares of Crinetics Pharmaceuticals in a research note on Friday, September 27th. Oppenheimer reiterated an “outperform” rating and issued a $73.00 price objective (down from $74.00) on shares of Crinetics Pharmaceuticals in a research note on Friday, August 9th. Citigroup raised their target price on Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a “buy” rating in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $90.00 price target on shares of Crinetics Pharmaceuticals in a research report on Monday, September 16th. Finally, HC Wainwright lifted their price objective on Crinetics Pharmaceuticals from $69.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $70.18.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.